Medpace (NASDAQ:MEDP) CEO Sells $8,739,177.75 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 13,995 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $624.45, for a total value of $8,739,177.75. Following the completion of the transaction, the chief executive officer directly owned 547,200 shares of the company’s stock, valued at $341,699,040. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Stock Performance

Shares of MEDP opened at $611.57 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock’s 50-day simple moving average is $562.52 and its 200 day simple moving average is $493.80. The stock has a market capitalization of $17.07 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the firm earned $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. bought a new stake in Medpace during the second quarter worth about $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC bought a new stake in Medpace in the 4th quarter worth approximately $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace in the second quarter worth approximately $30,000. Finally, Allied Private Wealth LLC purchased a new stake in Medpace in the second quarter worth approximately $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on MEDP shares. Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Robert W. Baird boosted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and raised their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.